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Enhancing bone morphogenetic protein (BMP) signaling increases bone formation in a variety of
settings that target bone repair. However, the role of BMP in themaintenance of adult bonemass
is not well understood. Targeted disruption of BMP3 in mice results in increased trabecular bone
formation, whereas transgenic overexpression of BMP3 in skeletal cells leads to spontaneous
fracture, consistent with BMP3 having a negative role in bone mass regulation. Here we investi-
gate the importance of BMP3 as a mediator of BMP signaling in the adult skeleton. We find that
osteoblasts (OBL) and osteocytes are the source of BMP3 in adult bone. Using in vitro cultures of
primary bone marrow stromal cells, we show that overexpression of BMP3 suppresses OBL differ-
entiation,whereas loss of BMP3 increases colony-formingunit fibroblasts and colony-formingunit
OBL. The ability of BMP3 to affect OBL differentiation is due to its interactionwith activin receptor
type 2b (Acvr2b) because knockdownof endogenous Acvr2b in bonemarrow stromal cells reduces
the suppressive effect of BMP3 on OBL differentiation. These findings best fit a model in which
BMP3, produced by mature bone cells, acts to reduce BMP signaling through Acvr2b in skeletal
progenitor cells, limiting their differentiation to mature OBL. Our data further support the idea
that endogenous BMPs have a physiological role in regulating adult bone mass. (Molecular
Endocrinology 26: 87–94, 2012)
Bone morphogenetic proteins (BMP) were identified assignals that induce ectopic bone formation through
effects on skeletal progenitor cells present in adult ani-
mals (1). In rodents, cellular targets for BMP include peri-
osteal cells, muscle satellite cells, vessel pericytes, and
bone marrow stromal cells (BMSC) (2–6). BMP signaling
is initiated when dimeric ligands associate with type I and
type II receptors that are transmembrane serine/threonine
kinases, forming a multimeric receptor ligand complex.
Within this complex, the constitutively activated type II
receptors serve a regulatory function by phosphorylating
type I receptors. The importance of type II receptor con-
trol of BMP signaling is reinforced by the recent finding
that fibrodysplasia ossificans progressiva, a genetic disor-
der of uncontrolled endochondral ossification in soft tis-
sue, is caused by a mutation that renders Alk2, a type I
BMP receptor, constitutively active and removed from
regulation by type II receptor (7, 8). Once activated, type
I receptors propagate BMP signals by phosphorylating
BMP-specific R-Smad1, -5, and -8 (canonical BMP sig-
naling), and also by phosphorylating MAPK such as Erk,
Jnk, and p38 (noncanonical BMP signaling) (9). Phos-
phorylated R-Smad form heteromeric complexes with
Smad4 and directly activate the transcription of BMP-
responsive genes (10, 11).
Although BMP have been successfully developed as
clinical tools for enhancing bone formation during tissue
regeneration, the potential of endogenous BMP signaling
to regulate bone mass is less well understood (12). Recent
studies employing administration of neutralizing anti-
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bodies or soluble receptor decoys found reducing the
availability of TGF- or activin leads to significant gains
in bone formation, identifying these factors as negative
regulators of adult bone mass (13–16). In contrast, en-
hanced BMP signaling appears to play a positive role,
because reducing the levels of the BMP antagonists nog-
gin or gremlin enhances bone formation in the adult skel-
eton (17, 18). BMP3, a receptor antagonist specific for the
type II receptor activin receptor type 2b (Acvr2b), appears
to serve a unique role in the adult skeleton. Adult mice
lacking BMP3 have increased bone mass, whereas mice
with increased BMP3 levels in bone show delayed endo-
chondral ossification with spontaneous rib fractures (19,
20). However, the cellular targets of BMP3 and the mo-
lecular mechanisms used by BMP3 to affect bone forma-
tion remain to be completely elucidated. In the present
study, we use a LacZ knock-in allele to the BMP3 locus
(BMP3 LacZ knock-in) to identify osteoblasts (OBL) and
osteocytes (OCY) as the bone cells responsible for BMP3
production in the adult skeleton. We show that BMP3
targets osteoprogenitor cells where it inhibits BMP signal-
ing. We define the interaction of BMP3/Acvr2b as a key
event in BMP-mediated OBL differentiation by demon-
strating that knockdown of endogenous Acvr2b dimin-
ishes the suppressive effect of BMP3 on osteoprogenitor
cells. In addition, we find that loss of BMP3 increases
colony-forming unit fibroblasts (CFU-F) and colony-
forming unit OBL (CFU-OB) in BMSC cultures. Taken
together, these data confirm that BMP3, secreted by OBL
and OCY, regulates trabecular bone formation by regu-
lating the differentiation of BSMC, thus identifying
BMP3 as a novel target for bone mass augmentation.
Results
BMP3 is expressed by OBL and OCY
Using Velocigene technology (21), a BMP3-null mouse
was generated where the first exon (encoding the N-ter-
minal part of the precursor region) was replaced in frame
with the lacZ reporter gene (BMP3 LacZ knock-in). To
examine skeletal expression of BMP3, we analyzed
heterozygousmice at 4wk of age and found thatOBL and
OCY are the source of BMP3 in adult bone (Fig. 1). These
data are in agreement with profiling data from Paic et al.
(21) who reported that BMP3 as well as Acvr2b tran-
scripts were present in OBL and OCY. We did not find
BMP3 expression in cartilage, osteoclasts, or skeletal pro-
genitor cells including those of the bone marrow stroma
or the outer layers of the periosteum, consistent with the
idea that BMP3 is a product of mature OBL lineage cells
(Fig. 1 and data not shown).
BMP3 inhibits Smad signaling and suppresses
OBL differentiation
We next wanted to determine the effects of BMP3 on
skeletal progenitor cell differentiation in vitro. As a
source for BMP3 protein, we transfected W20-17 cells
with BMP3 expression vectors. W20-17 cells are an os-
teoprogenitor cell line that requires BMP signaling for OB
differentiation (2). Conditioned medium from W20-17
cells transfected with control or BMP3 containing
pcDEF3 expression vectors were analyzed by Western
blot, and BMP3 expression was verified (Fig. 2A). We
then examined the effects of overexpression of BMP3 in
skeletal progenitor cells and found that it suppressed the
osteogenic activity of BMP4 and BMP2 in all cells exam-
ined including W20-17 (Fig. 2, B and C); ST2, a mouse
bone marrow stromal cell line (Fig. 2D); and primary
BSMC (Fig. 2E). Furthermore, BMP3 also suppressed ex-
pression of osteocalcin, a marker of mature OBL in cells
treated with osteogenic BMP (Fig. 2F). To determine
whether the inhibitory effects of BMP3 target canonical
BMP signaling, we analyzed phosphorylation of endoge-
FIG. 1. OBL and OCY express BMP3. Tibia from BMP3 4-wk-old LacZ
knock-in mice stained for -galactosidase. Diaphyseal region is shown
in the top panel. The boxed areas in the upper panel are shown as
magnified images (20) of cortical bone (CB) and trabecular bone (TB)
in lower panels. Arrowheads and arrows indicate OBL and OCY,
respectively. BM, Bone marrow; PO, periosteum.
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nous Smad1/5/8 byWestern blotting and activation of the
IdWTF4 BMP-responsive reporter in W20-17 cells. Al-
though transfection of cells with BMP4 or BMP2 resulted
in increased p-Smad1/5/8 levels and robustly activated
IdWTF4-luc, coexpression of BMP3 reduced BMP4-
induced phosphorylation of Smad1/5/8 (Fig. 3A) and also
suppressed IdWT4F-luc reporter activity induced by co-
expression of BMP4 (Fig. 3B) or BMP2
(Fig. 3C) in a dose-dependent manner.
BMP3 appeared to directly suppress
BMP signaling and not act by changing
levels of BMP antagonists, because
transcript levels for chordin, noggin,
and gremlin were not altered in mouse
BSMC treatedwith BMP3-conditioned
media (data not shown).
Suppressive effects of BMP3 on
OBL differentiation require Acvr2b
We previously reported that BMP3
interferes with BMP signaling by bind-
ing to the multifunctional type II BMP/
activin receptor Acvr2b (22). Allen-
dorph et al. (23) confirmed these data
by showing that BMP3 receptor speci-
ficity for Acvr2b is controlled through
the interaction of lysine 30 of BMP3
and glutamic acid 76 of Acvr2b. To
investigate whether BMP3 suppresses
OB differentiation via its specific inter-
action with Acvr2b, we examined the
effects of BMP3 on cells in which en-
dogenous Acvr2b had been knocked
down using small interfering RNA
(siRNA). As a first step, we confirmed
that W20-17 cells express Acvr2b and
found that Acvr2b is the most abundant type II BMP
receptor in these cells (Fig. 4A). We next confirmed that
transfection of W20-17 cells with siRNA specific for
Acvr2b significantly reduced protein levels of endogenous
Acvr2b in Western blots (60% knockdown) when com-
paredwith control/scrambled RNAoligonucleotides (Fig.
FIG. 2. BMP3 suppresses OBL differentiation induced by BMP in osteoprogenitor cells. A,
Western blot of conditioned medium from W20-17 cells transfected with empty vector or
BMP3 verifies BMP3 expression. B and C, W20-17 cells were transfected with empty vector or
BMP3, and then ALP activity was stimulated by cotransfection with BMP2 or BMP4. BMP3
significantly reduced the BMP-induced ALP activity. D and E, ST2 cells and primary BSMC that
had been transfected with BMP4 to stimulate ALP activity were treated with control (vector)
or BMP3-conditioned medium from W20-17 cells. BMP3-conditioned medium reduced ALP
activity in both cell types. F, W20-17 cells cotransfected with BMP3 and BMP4 expressed
reduced levels of osteocalcin (OC) on d 3, as determined by quantitative real time PCR
analysis. Data are shown as the mean  SD (n  3). *, P  0.05; **, P  0.01 in comparison
with cells transfected or treated with an empty vector (Vec) or conditioned medium from
empty vector-transfected cells in each group.
FIG. 3. BMP3 suppresses BMP-Smad signaling. A, W20-17 cells were cotransfected with empty vector or BMP3 along with BMP4. At 24 h after
transfection, protein levels were determined by Western blot. The protein levels were quantified by using Image J software. Smad1 was used for
protein normalization. BMP3 reduced the amount of phospho- (P-)Smad1/5/8 induced by BMP4. B and C, W20-17 cells were cotransfected with 0,
30, 60, or 90 ng BMP3 expression vector or 0, 30, 60, or 90 ng empty vector along with 45 ng IdWT4F-luc reporter and 15 ng phRL-SV40 internal
control vector. Luciferase activity was then stimulated by transfection of 50 ng BMP4 expression vector (B) or 50 ng BMP2 expression vector (C).
BMP3 was able to reduce the luciferase activity induced by both BMP4 and BMP2. Data are shown as the mean  SD (n  3). **, P  0.01 in
comparison with cells transfected with an empty vector and BMP4 or BMP2 in each group.
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4B). We then tested the ability of BMP3 to reduce BMP4-
mediated IdWT4F-luc and alkaline phosphatase (ALP)
activation in the Acvr2b knockdown cells. We found that
BMP3 could no longer block BMP4 activation of the BMP
luciferase reporter (Fig. 4C) or induction of ALP activity
(Fig. 4D), consistent with the finding that BMP3 binds
and acts specifically through Acvr2b (24, 25). To confirm
our RNA interference (RNAi) studies, we used C2C12
cells, which have been reported to lack expression of
Acvr2b and should prevent them from being targeted by
BMP3 (23–25). Although we detected low levels of
Acvr2b by quantitative PCR in our C2C12 cells (Fig. 4E),
we found that BMP3 was unable to block ALP activity
induced by BMP treatment (Fig. 4F). Taken together,
these findings confirm that the suppressive effect of BMP3
on OBL differentiation requires Acvr2b.
Absence of BMP3 increases CFU-F and CFU-OB
from BMSC
If endogenous BMP3 functions to regulate OBL differ-
entiation from BMSC, then mice lacking BMP3 should
have an enhanced basal level of OBL differentiation. To
investigate this idea, we harvested BMSC from BMP3-
null mice and wild-type littermates and tested these cells
in standardCFU-F andCFU-OB assays. BSMC that reside
in a BMP3-null environment show an increase in CFU-F
colony number and colony size (Fig. 5, A and B). In ad-
dition, the number of ALP-positive colonies produced by
BMSC from mice lacking BMP3 and their spontaneous
differentiation into OBL-lineage cells was significantly
increased in the absence of exogenous osteogenic signals
when comparedwithwild-type controls (Fig. 5, C andD).
These data confirm that loss of BMP3 results in increased
differentiation of early OBL precursors into mature OBL
and further suggest a negative role for BMP3 in adult
bone.
Discussion
In the present study, we examined the cellular targets and
molecular mechanisms that underlie the inhibition of
BMP-induced OBL differentiation by BMP3, leading to
the high-bone-mass phenotype in the BMP3 knockout
FIG. 4. BMP3 suppresses BMP signaling via Acvr2b. A, Transcript levels of BMPR-II, Acvr2a, and Acvr2b were determined in W20-17 cells using
quantitative real-time PCR. B–D, W20-17 cells were transfected with siRNA specific for Acvr2b or a scrambled siRNA. B, Western blot analysis on d
1 shows the level of endogenous Acvr2b was reduced 60% using siRNA for Acvr2b. The protein levels were quantified by using Image J software.
-Actin was used for protein normalization. The siRNA specific for Acvr2b reduced the suppressive effect of BMP3 on IdWT4F-luc activity (C) and
ALP activity (D) induced by BMP4 in W20-17 cells. E, Transcript levels of BMPR-II, Acvr2a, and Acvr2b were determined in C2C12 cells by
quantitative real-time PCR. F, Cotransfection of BMP3 did not suppress ALP activity induced by cotransfection of BMP2 in C2C12 cells. Data are
shown as the mean  SD (n  3). *, P  0.05; **; P  0.01.
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mice (19, 22, 23). We demonstrate that this inhibition is
due to the interaction of BMP3 with the type II recep-
tor, Acvr2b, present on skeletal progenitor cells. BMP3/
Acvr2b binding occurs upstream of type I receptor
function, an idea confirmed by the observation that over-
expression of BMP3 could not suppress IdWT4F-luc ac-
tivity induced by a constitutively active Smad1 (Supple-
mental Fig. 1, published on The Endocrine Society’s
Journals Online web site at http://mend.endojournals.
org) and in agreement with results obtained previously in
Xenopus embryo studies (22). These data suggest an im-
portant regulatory role for type II BMP receptors in the
process of bone formation in the adult skeleton, an idea
supported by the pathological endochondral ossification
that occurs when type II receptor control is bypassed in
fibrodysplasia ossificans progressiva (7, 8).
Our results show that in adult bone, BMP3 is produced
by OBL and OCY. Removing BMP3 from the bone envi-
ronment increased CFU-F colony number and colony size
as well as the spontaneous differentiation of osteopro-
genitors into bone-forming cells. These data suggest a
model of BMP3 activity in the skeleton whereby BMP3
produced by mature bone cells acts to limit the differen-
tiation of Acvr2b-positive osteoprogenitors residing in
the bone marrow microenvironment (Fig. 6). Osteopro-
genitors not only express Acvr2b but also have other type
II receptors (Acvr2a, BMPR-II, and transforming growth
factor beta type II receptor) that are used by BMP/TGF-
/activin ligands to regulate signal transduction in bone.
This fact is highlighted by recent data showing that sys-
temic administration of a TGF- neutralizing antibody to
adultmice increasedbonemass andbonedensity, suggesting
that TGF- signaling via transforming growth factor beta
type II receptor onBMSC limits osteogenesis (13, 14, 26). In
addition, systemic administration of AR2AFc (soluble ac-
tivin type II A receptor) and AR2BFc (soluble activin type II
B receptor) type II activin receptor decoys also increases
bonemass in vivo, andadministrationofAR2AFc toBMP3-
nullmice further increases bonemineral density (15, 16, 27).
Taken as a whole, these data point to the potential thera-
peutic benefits of increasing bone forma-
tion throughmodulating the interactions
between type II receptors and BMP/
TGF-/activins and suggest that BMP3
and its specific interaction with Acvr2b




BMP3/ mice were previously gener-
ated and described elsewhere (19). BMP3
LacZ knock-in mice were generated at Re-
generon Pharmaceuticals using Velocigene
technology (28). The region of the BMP3
gene containing exon 1 was deleted and
replaced with a transmembrane-lacZ/neo
FIG. 6. Model for BMP3 control of BMSC differentiation in the bone marrow
microenvironment. BMP3 produced by OBL and OCY interacts with Acvr2b present on BMSC
to suppress OBL differentiation and maturation induced by BMP. In addition, because OBL
and OCY express Acvr2b, BMP3 may also effect BMP signaling and gene expression in these
cells as a means of regulating adult bone mass.
FIG. 5. Absence of BMP3 increases CFU-F and CFU-OB in BMSC
cultures. BMSC were plated in six-well plates at two different densities
(1.0  106 or 1.5  106 cells per well). CFU-F (A) and cell number per
colony (B) were evaluated after 10 d culture using methylene green
staining. BSMC from BMP3/ mice had increased CFU-F colony
number and colony size when compared with wild-type (WT) controls.
The appearance of CFU-OB was assessed by ALP (C) and alizarin red
staining (D) after 10 or 28 d, respectively. The density of ALP staining
was quantified by using Image J software. The number of ALP- and
alizarin red-positive colonies was increased in BSMC from BMP3/
mice when compared with wild-type control mice. *, P  0.05.
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cassette using bacterial homologous recombination. All studies
performed were approved by the Institutional Animal Care and
Use Committee at Harvard Medical School (Boston, MA).
X-gal staining
Tibias were collected from 4-wk-old BMP3 LacZ knock-in
mice and littermate controls. Tissues were fixed for 24 h at 4 C
in 4% paraformaldehyde/PBS (pH 8), decalcified at 4 C in 0.5 M
EDTA (pH 7.4) for 10–14 d, equilibrated in 15% sucrose for
1 h, 30% sucrose overnight at 4 C, and cryo-embedded. For
X-gal staining, 20-m sections were postfixed in 4% parafor-
maldehyde, washed three times for 15 min in 2 mM MgCl2,
0.01% sodium deoxycholate, 0.02% Nonidet P-40 in PBS,
stained overnight in 0.1%X-gal, 5 mM potassium ferrocyanide,
5 mM potassium ferricyanide in PBS (pH 8) overnight at 37 C,
and counterstained with eosin/floxin (29).
Plasmids
Plasmids encoding wild-type human BMP3 (accession num-
ber NM_001201.2) were obtained by a standard RT-PCR tech-
nique using PrimeSTARHS DNA polymerase (TaKaRa, Ohtsu,
Japan) and cloned into a pcDEF3 expression vector (30). The
human BMP2, BMP4, mouse constitutively active Smad1, and
IdWT4F-luc reporter plasmids have been previously described
(10, 31).
Cell culture and transfection
W20-17 cells were cultured andmaintained as described pre-
viously (2). ST2 cells were purchased from the RIKENCell Bank
(Tsukuba, Japan). ST2 cells were cultured and maintained in
-MEM supplemented with 10% fetal bovine serum. Primary
BSMC were collected from femurs and tibias of 6-wk-old wild-
type C57BL/6J mice or BMP3/ mice. After epiphyses were
removed, bone was flushed with 15 ml -MEM using a 20-ml
syringe fitted with a 23-gauge needle. Flushed bone marrow
cells were cultured with -MEM containing 15% fetal bovine
serum for 4 d (32). Cells were transfected with plasmids using
Lipofectamine 2000 (Invitrogen) (33). Conditioned media were
collected from W20-17 cells 3 d after transfection with empty
vector, BMP3, or BMP4 for each assay.
ALP and luciferase assays
ALP activity was measured as a marker of OBL differentia-
tion on d 2. Cells treated with an acetone/ethanol (50:50) mix-
ture were incubatedwith a substrate solution composed of 0.1 M
diethanolamine, 1 mMMgCl2, and 1 mg/ml p-nitrophenylphos-
phate. The reaction was terminated by adding 3 M NaOH, and
absorbance values were measured at 405 nm (34, 35). Lu-
ciferase assays were performed using IdWT4F-luc, phRL-SV40
(Promega, Madison, WI) with the Dual-Glo Luciferase Assay
System (Promega) (36).
CFU-F and CFU-OB assay
Primary BSMC were plated in triplicate cultures (six-well
plates) at two different densities (1.0 106 or 1.5 106 cells per
well). The formation of CFU-F andCFU-OBwas evaluated after
10 and 28 d of culture. At the end of each experiment, cultures
were washed twice with PBS and fixed with cold ethanol, and
CUF-F were stained with methylene green, and colonies with
more than 50 cells were counted. For CFU-OB assays, forma-
tion of OBL progenitors and OBL was detected using ALP and
alizarin red staining (37). For ALP staining, cells were incubated
for 20 min with a mixture of 0.1 mg/ml naphthol AS-MX phos-
phate (Sigma-Aldrich Chemicals, St. Louis, MO), 0.5% N,N-
dimethylformamde, 2 M MgCl2, and 0.6 mg/ml fast red TR salt
(Sigma-Aldrich) in 0.1 M Tris-HCl (pH 8.5) at room tempera-
ture. The density of ALP staining was quantified by using Image
J (National Institutes of Health, Bethesda, MD) software. For
alizarin red staining, the cells were immersed in a 40mM alizarin
(Sigma-Aldrich) solution (pH 4.2) for 20 min at room temper-
ature with gentle agitation. The solution then was removed, and
the mineralized matrices were washed with water.
Trichloroacetic acid (TCA) precipitation
To concentrate the BMP3 protein, TCA precipitation was
performed on medium collected from W20-17 cells that were
transfected with BMP3 expression vectors. A 25-ml volume of
medium was collected, and 10 times the sample volume of 10%
TCA was added and incubated on ice for 1.5 h. This was fol-
lowed by centrifugation at 4000 g for 15min at 4 C. The TCA
was aspirated, 400 l acetone was added, and the sample was
vortexed vigorously and then centrifuged at 12000  g for 10
min at 4 C. The acetone was aspirated, and the sample was dried
at room temperature for 5 min. Finally, lysis buffer was added,
and the sample incubated at 37 C for 5 min before Western blot
analysis (38).
Western blot analysis
The following antibodies were used for Western blot analy-
sis: anti-BMP3 polyclonal antibody, anti-Acvr2b polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
phosphorylated Smad1/5/8 polyclonal antibody, anti-Smad1
polyclonal antibody (Cell Signaling, Beverly, MA), and anti--
actin mouse monoclonal antibody (Sigma-Aldrich). The target
proteins were detected using a horseradish peroxidase-conju-
gated antimouse, antirabbit IgG antibody (Cell Signaling), or
anti-goat IgG antibody (Santa Cruz). Protein levels were quan-
tified using Image J software.
Reverse transcription and quantitative
PCR analysis
Total RNA was isolated from W20-17 cells using Trizol
(Invitrogen, Carlsbad, CA) and then reverse transcribed into
cDNA using Superscript III (Invitrogen). The cDNA was ampli-
fied by PCR using specific primers for murine osteocalcin
(primer sequences: forward, agactccggcgctacctt; reverse, ctcgt-
cacaagcagggttaag), BMPR-II (primer sequences: forward, gagc-
cctcccttgacctg; reverse, gtatcgaccccgtccaatc), Acvr2a (primer
sequences: forward, ccctcctgtacttgttcctactca; reverse, gcaatggctt
caaccctagt), Acvr2b (primer sequences: forward, tggctgttcggttt-
gagc; reverse, ggccatgtaccgtctggt), and -actin. Quantitative
real-time PCR was performed using the Roche (Indianapolis,
IN) Light Cycler 480 Real-time PCR system with probe-based
detection (Universal Probe Library; Roche). Values were nor-
malized to -actin using the 2-Ct method (39).
RNAi transfection
RNAi Stealth oligonucleotides were designed against murine
Acvr2b (no. MSS201683; Invitrogen), and a scrambled RNAi
was used as a negative control (Invitrogen). Cells were trans-
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fected with siRNA using N-TERNanoparticle siRNA Transfec-
tion System according to the manufacturer’s instructions
(Sigma-Aldrich).
Statistical analysis
Comparisons were made using an unpaired Student’s t test;
the results are shown as means  SD. Statistical significance is
indicated as P  0.05 or P  0.01.
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